<HTML dir=ltr><HEAD>
<META http-equiv=Content-Type content="text/html; charset=unicode">
<STYLE><!--
.hmmessage P
{
margin:0px;
padding:0px
}
body.hmmessage
{
font-size: 10pt;
font-family:Tahoma
}
--></STYLE>
<META content="MSHTML 6.00.6000.17080" name=GENERATOR></HEAD>
<BODY class=hmmessage>
<DIV id=idOWAReplyText14040 dir=ltr>
<DIV dir=ltr><FONT face=Arial color=#000000 size=2>Dear Poonam,</FONT></DIV>
<DIV dir=ltr><FONT face=Arial></FONT> </DIV>
<DIV dir=ltr><FONT face=Arial>Have you work on Leishmania in the clinical samples directly ?</FONT></DIV>
<DIV dir=ltr><FONT face=Arial></FONT> </DIV>
<DIV dir=ltr><FONT face=Arial>Should you work with promastigotes grown from the clinical samples, how many samples have you isolated in culture for continuous passasge successfully ? Did you have clinical samples which gave you no growth or very limited growth and not subculturable ? </FONT></DIV>
<DIV dir=ltr><FONT face=Arial></FONT> </DIV>
<DIV dir=ltr><FONT face=Arial>KP</FONT></DIV></DIV>
<DIV dir=ltr><BR>
<HR tabIndex=-1>
<FONT face=Tahoma size=2><B>From:</B> leish-l-bounces@lineu.icb.usp.br on behalf of poonam salotra<BR><B>Sent:</B> Fri 6/17/2011 6:24 AM<BR><B>To:</B> rreithinger@yahoo.co.uk; abhay.satoskar@osumc.edu; jdavid@hsph.harvard.edu; alan.magill@us.army.mil; Chang, Kwang-Poo<BR><B>Cc:</B> raj@cellabs.com.au; vishwamohan_katoch@yahoo.co.in; leish-l@lineu.icb.usp.br<BR><B>Subject:</B> Re: [Leish-l] Thermotherapy<BR></FONT><BR></DIV>
<DIV>
<DIV dir=ltr>
<DIV dir=ltr>Dear KP,<BR>To answer your question about the <FONT face=Arial>HIV-CL patient located in India that we reported in Lancet 2011, this case was identified in Rajasthan state in Western India. We had identified the causative parasite as L tropica based on ITS1-PCR-RFLP analysis.</FONT><BR><FONT face=Arial>In all our studies with CL patients in Rajasthan, we found L tropica as the causative agent (Immunology, 2010; FEMS Imm.Med.Micro, 2009; AmJTropMedHyg 2007). Heat therapy introduced by Abhay in this region seems to be working very well. </FONT></DIV><FONT face=Arial></FONT> <BR><FONT face=Arial>Best regards</FONT><BR><FONT face=Arial>Poonam</FONT><BR>
<DIV dir=ltr><BR><FONT face=Arial></FONT> <FONT face=Arial>.................................<BR>Poonam Salotra, PhD<BR>Deputy Director<BR>Institute of Pathology (ICMR)<BR>Safdarjung Hospital Campus<BR>New Delhi-110029<BR>India<BR>Ph 91-11-26166124<BR>Fax 91-11-26198401</FONT><BR> <BR></DIV>
<DIV dir=ltr>
<HR id=stopSpelling>
Date: Wed, 15 Jun 2011 13:57:29 +0100<BR>From: rreithinger@yahoo.co.uk<BR>To: Abhay.Satoskar@osumc.edu; jdavid@hsph.harvard.edu; ALAN.MAGILL@US.ARMY.MIL; KwangPoo.Chang@rosalindfranklin.edu<BR>CC: raj@cellabs.com.au; vishwamohan_katoch@yahoo.co.in; leish-l@lineu.icb.usp.br<BR>Subject: Re: [Leish-l] Thermotherapy<BR><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>
<TBODY>
<TR>
<TD vAlign=top>
<DIV class=ecxrprt_all>
<DIV class="ecxrprt ecxabstract">
<DIV class=ecxaux>
<DIV class=ecxresc>
<DL class=ecxrprtid>
<DD></DD></DL></DIV>
<DIV class=ecxlinks> </DIV>
<DIV class=ecxlinks>For one of the patients:</DIV>
<DIV class=ecxlinks> </DIV></DIV></DIV>
<DIV class="ecxrprt ecxabstract">
<P class=ecxMsoNormal style="BACKGROUND: white; LINE-HEIGHT: normal"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><A title=Lancet. href="http://www.ncbi.nlm.nih.gov/pubmed/21315946" target=_blank><SPAN style="COLOR: blue">Lancet.</SPAN></A> 2011 Feb 12;377(9765):610.</SPAN></P></DIV>
<P class=ecxMsoNormal style="BACKGROUND: white; LINE-HEIGHT: normal"><B><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Heat, Oriental sore, and HIV.</SPAN></B></P></DIV>
<P class=ecxMsoNormal style="BACKGROUND: white; LINE-HEIGHT: normal"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Prasad N"[Author]' target=_blank><SPAN style="COLOR: blue">Prasad N</SPAN></A>, <A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Ghiya BC"[Author]' target=_blank><SPAN style="COLOR: blue">Ghiya BC</SPAN></A>, <A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Bumb RA"[Author]' target=_blank><SPAN style="COLOR: blue">Bumb RA</SPAN></A>, <A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Kaushal H"[Author]' target=_blank><SPAN style="COLOR: blue">Kaushal H</SPAN></A>, <A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Saboskar AA"[Author]' target=_blank><SPAN style="COLOR: blue">Saboskar AA</SPAN></A>, <A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Lezama-Davila CM"[Author]' target=_blank><SPAN style="COLOR: blue">Lezama-Davila CM</SPAN></A>, <A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Salotra P"[Author]' target=_blank><SPAN style="COLOR: blue">Salotra P</SPAN></A>, <A href='http://www.ncbi.nlm.nih.gov/pubmed?term="Satoskar AR"[Author]' target=_blank><SPAN style="COLOR: blue">Satoskar AR</SPAN></A>.</SPAN>
<DIV></DIV>
<P class=ecxMsoNormal style="LINE-HEIGHT: normal"><SPAN style="FONT-SIZE: 10pt"><FONT face=Calibri></FONT></SPAN>
<DIV></DIV>
<DIV class=ecxcit><BR><BR>--- On <B>Wed, 15/6/11, Chang, Kwang-Poo <I><KwangPoo.Chang@rosalindfranklin.edu></I></B> wrote:<BR></DIV>
<DIV></DIV>
<DIV></DIV>
<BLOCKQUOTE style="PADDING-LEFT: 5px; MARGIN-LEFT: 5px; BORDER-LEFT: rgb(16,16,255) 2px solid"><BR>From: Chang, Kwang-Poo <KwangPoo.Chang@rosalindfranklin.edu><BR>Subject: RE: Thermotherapy<BR>To: "Satoskar, Abhay" <Abhay.Satoskar@osumc.edu>, "Richard Reithinger" <rreithinger@yahoo.co.uk>, "John David" <jdavid@hsph.harvard.edu>, "Alan J COL MIL USA MEDCOM WRAIRMagill" <ALAN.MAGILL@US.ARMY.MIL><BR>Cc: vishwamohan_katoch@yahoo.co.in, "Raj" <raj@cellabs.com.au>, leish-l@lineu.icb.usp.br<BR>Date: Wednesday, 15 June, 2011, 13:41<BR><BR>
<DIV id=ecxyiv766059484>
<STYLE>
</STYLE>
<STYLE>
.ExternalClass #ecxyiv766059484 P
{margin-bottom:0px;}
</STYLE>
<DIV id=ecxyiv766059484idOWAReplyText46487 dir=ltr>
<DIV dir=ltr><FONT face=Arial color=#000000 size=2>Dear Abhay,</FONT></DIV>
<DIV dir=ltr><FONT face=Arial size=2></FONT> </DIV>
<DIV dir=ltr><FONT face=Arial size=2>Where are your HIV-CL patients located in India ? Are these PKDL or CL caused by something else ?</FONT></DIV>
<DIV dir=ltr><FONT face=Arial size=2></FONT> </DIV>
<DIV dir=ltr><FONT face=Arial size=2>KP</FONT></DIV></DIV>
<DIV dir=ltr><BR>
<HR tabIndex=-1>
<FONT face=Tahoma size=2><B>From:</B> Satoskar, Abhay [mailto:Abhay.Satoskar@osumc.edu]<BR><B>Sent:</B> Wed 6/15/2011 6:33 AM<BR><B>To:</B> Richard Reithinger; Chang, Kwang-Poo; John David; Alan J COL MIL USA MEDCOM WRAIRMagill<BR><B>Cc:</B> vishwamohan_katoch@yahoo.co.in; Raj; leish-l@lineu.icb.usp.br<BR><B>Subject:</B> RE: Thermotherapy<BR></FONT><BR></DIV>
<DIV dir=ltr>
<DIV style="FONT-SIZE: x-small; COLOR: #000000; DIRECTION: ltr; FONT-FAMILY: Tahoma">
<DIV>All,</DIV>
<DIV><FONT face=tahoma>I think there some interesting<A target=_blank rel=nofollow></A> discussions here. I think its worth trying anesthetic<A target=_blank rel=nofollow></A> cream for heat therapy. We will do that. As Richard indicated that the greatest advantage of RF<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A> therapy ( even if it need local anesthesia with lidocaine<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A>) is that in most patient just one treatment for 1 min is enough to induce complete clinical cure. More importantly, in India we had three HIV patients with CL who failed to respond to intralesional<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A> SSG<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A> even after their CD4<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A>+ T cell counts increasing to > 200 after starting HAART<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A>. These patients were treated<A target=_blank rel=nofollow></A> with RF<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A> therapy which resulted in complete lesion healing in 5-6 weeks. The patients have remained disease free after 1.5 years. As we know treating CL in HIV patients can be difficult so I think we have an effective alternative.</FONT></DIV>
<DIV><FONT face=tahoma></FONT> </DIV>
<DIV><FONT face=tahoma><FONT face=tahoma><FONT face=tahoma><A target=_blank rel=nofollow><FONT face=tahoma>Abhay</FONT></A></FONT></FONT></FONT></DIV>
<DIV> </DIV>
<DIV>
<DIV><FONT face=Tahoma size=2><A target=_blank rel=nofollow></A><FONT face=Tahoma size=2><A target=_blank rel=nofollow></A></FONT><FONT face=Tahoma size=2><FONT face=Tahoma size=2>Abhay</FONT></FONT> R Satoskar<A target=_blank rel=nofollow></A><A target=_blank rel=nofollow></A> MD, PhD</FONT></DIV>
<DIV><FONT face=tahoma size=2>Professor</FONT></DIV>
<DIV><FONT face=tahoma size=2>Departments of Pathology and Microbiology</FONT></DIV>
<DIV><FONT face=tahoma size=2>129 Hamilton Hall</FONT></DIV>
<DIV><FONT face=tahoma size=2>1645 Neil Avenue</FONT></DIV>
<DIV><FONT face=tahoma size=2>The Ohio State University</FONT></DIV>
<DIV><FONT face=tahoma size=2>Columbus, Ohio</FONT></DIV>
<DIV><FONT face=tahoma size=2>Tel: 614-366-3417</FONT></DIV></DIV>
<DIV dir=ltr><FONT face=Tahoma color=#000000 size=2></FONT> </DIV>
<DIV id=ecxyiv766059484divRpF759665 style="DIRECTION: ltr">
<HR tabIndex=-1>
<FONT face=Tahoma color=#000000 size=2><B>From:</B> Richard Reithinger [rreithinger@yahoo.co.uk]<BR><B>Sent:</B> Wednesday, June 15, 2011 4:02 AM<BR><B>To:</B> Kwang-PooChang; John David; Alan J COL MIL USA MEDCOM WRAIRMagill<BR><B>Cc:</B> Satoskar, Abhay; vishwamohan_katoch@yahoo.co.in; Raj; leish-l@lineu.icb.usp.br<BR><B>Subject:</B> Thermotherapy<BR></FONT><BR></DIV>
<DIV></DIV>
<DIV>
<TABLE cellSpacing=0 cellPadding=0 border=0>
<TBODY>
<TR>
<TD vAlign=top>
<DIV> </DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'">All, </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'"></SPAN> </DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'">Agree with Alan: patients need at least intradermal anesthesia prior application of radiofrequency waves using the ThermoMed device; 50C is way to high for someone to endure for 5 min or so. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'"></SPAN> </DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'">The reason the device appears to work better than other similar approaches is that the radiofrequencies yield a relatively homogenous/stable field where skin particles get excited, and in turn generate the heat; the heat (temperature) is then controlled by a thermistor embedded in the device. Following application of radiofrequency-generated heat, application of a topical antibiotic is recommended to avoid post-treatment secondary infections. From an operational point of view we also know that the ThermoMed device is more useful in situations where (i) you have lots of patients (i.e. economies of scale); (ii) patients with smaller lesions; and (iii) patient with lesions that are not located on joint or body areas that are difficult to access. Whilst a clear disadvantage of the device has been cost, the advantages have been that many patients only require one application session of radiofrequency-generated heat (i.e. patient lost to follow-up are not an issue) and that the device is portable (e.g. can be used in mobile-type of treatment service provision).</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'"></SPAN> </DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'">Having said, I second Tony Bryceson's comment, that there is scope for additional well-designed and carried out clinical trials looking at this approach, comparing it to IM/IV or IL SbV or other treatment modalities.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'"></SPAN> </DIV>
<DIV><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'sans-serif'">Richard Reithinger</SPAN></DIV>
<DIV><BR>--- On <B>Wed, 8/6/11, Magill, Alan J COL MIL USA MEDCOM WRAIR <I><ALAN.MAGILL@US.ARMY.MIL></I></B> wrote:<BR></DIV>
<BLOCKQUOTE style="PADDING-LEFT: 5px; MARGIN-LEFT: 5px; BORDER-LEFT: rgb(16,16,255) 2px solid"><BR>From: Magill, Alan J COL MIL USA MEDCOM WRAIR <ALAN.MAGILL@US.ARMY.MIL><BR>Subject: Re: [Leish-l] inquiry<BR>To: "Chang, Kwang-Poo" <KwangPoo.Chang@rosalindfranklin.edu>, "John David" <jdavid@hsph.harvard.edu><BR>Cc: "Satoskar, Abhay" <Abhay.Satoskar@osumc.edu>, "vishwamohan_katoch@yahoo.co.in" <vishwamohan_katoch@yahoo.co.in>, "Raj" <raj@cellabs.com.au>, "leish-l@lineu.icb.usp.br" <leish-l@lineu.icb.usp.br><BR>Date: Wednesday, 8 June, 2011, 20:45<BR><BR>
<DIV class=ecxyiv766059484plainMail>John certainly knows well..<BR><BR>50C is not tolerable to human skin. All potential lesions to be treated need to be appropriately cleaned and anesthetized with intradermal and subQ injection of lidocaine. I have never tried the newer lidocaine creams such as EMLA, they might work as well. This can be somewhat rate limiting for multiple lesions as each lesion needs to be prepared, injected, and you need to wait about 10 plus minutes for the lidocaine to work.<BR><BR>Trying the Thermomed device on normal skin (try on yourself) will show that most people can only get to about 43 or 44 C before quickly removing the device from their skin.<BR><BR>Alan Magill<BR><BR><BR>________________________________<BR>From: <A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=leish-l-bounces@lineu.icb.usp.br" target=_blank rel=nofollow>leish-l-bounces@lineu.icb.usp.br</A> [<A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=leish-l-bounces@lineu.icb.usp.br" target=_blank rel=nofollow>leish-l-bounces@lineu.icb.usp.br</A>] On Behalf Of Chang, Kwang-Poo [<A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=KwangPoo.Chang@rosalindfranklin.edu" target=_blank rel=nofollow>KwangPoo.Chang@rosalindfranklin.edu</A>]<BR>Sent: Monday, June 06, 2011 12:02 PM<BR>To: John David<BR>Cc: Satoskar, Abhay; <A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=vishwamohan_katoch@yahoo.co.in" target=_blank rel=nofollow>vishwamohan_katoch@yahoo.co.in</A>; Raj; <A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=leish-l@lineu.icb.usp.br" target=_blank rel=nofollow>leish-l@lineu.icb.usp.br</A><BR>Subject: Re: [Leish-l] inquiry<BR><BR>Any chance to make it available for additional trials elsewhere ?<BR><BR>I recall your statement in our conversation about the advantage of this instrument over the heating lamp. That is to maintain the specific elevated temperature uniformly throughout the skin lesion for a sustained period. The 50 C must be the effective temperature that has been experimentally determined. It seems to be a tolerable temperature to human skin ? Dr. Sharma may comment on this medically as a dermatologist ?<BR><BR>KP<BR><BR>________________________________<BR>From: John David [mailto:<A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=jdavid@hsph.harvard.edu" target=_blank rel=nofollow>jdavid@hsph.harvard.edu</A>]<BR>Sent: Sunday, June 05, 2011 11:18 PM<BR>To: Chang, Kwang-Poo<BR>Cc: Sharmanl; Satoskar, Abhay; Raj; Petr Volf; <A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=leish-l@lineu.icb.usp.br" target=_blank rel=nofollow>leish-l@lineu.icb.usp.br</A>; <A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=hgoto@usp.br" target=_blank rel=nofollow>hgoto@usp.br</A>; <A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=elfadil_abass@yahoo.com" target=_blank rel=nofollow>elfadil_abass@yahoo.com</A>; <A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=vishwamohan_katoch@yahoo.co.in" target=_blank rel=nofollow>vishwamohan_katoch@yahoo.co.in</A><BR>Subject: Re: [Leish-l] inquiry<BR><BR>The Themomed instrument shown below can produce accurate 50 degrees C plus or minus 0.2 degrees temperature by radio wave.<BR>from Themorsurgery Technologies. Picture below.<BR>Two papers of a trial in Brazil and one in Afghanistan on CL below.<BR>_______________________________________________<BR>Leish-l mailing list<BR><A href="http://uk.mc256.mail.yahoo.com/mc/compose?to=Leish-l@lineu.icb.usp.br" target=_blank rel=nofollow>Leish-l@lineu.icb.usp.br</A><BR><A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target=_blank rel=nofollow>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</A><BR></DIV></BLOCKQUOTE></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV></BLOCKQUOTE></TD></TR></TBODY></TABLE><BR>_______________________________________________ Leish-l mailing list Leish-l@lineu.icb.usp.br http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</DIV></DIV></DIV></BODY></HTML>